University of Groningen

Authors' Response to Brailon's Comment on: "Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants"

Simoons, Mirjam; Seldenrijk, Adrie; Mulder, Hans; van Roon, Eric; Bakker, Roberto; Ruhé, Henricus

Published in:
Drug Safety

DOI:
[10.1007/s40264-018-0716-5](https://doi.org/10.1007/s40264-018-0716-5)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2018

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Simoons, M., Seldenrijk, A., Mulder, H., van Roon, E., Bakker, R., & Ruhé, H. (2018). Authors' Response to Brailon's Comment on: "Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring". *Drug Safety*, 41(12), 1417-1418. <https://doi.org/10.1007/s40264-018-0716-5>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Authors' Response to Braillon's Comment on: "Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring"

Mirjam Simoons^{1,2,3} · Adrie Seldenrijk^{2,4} · Hans Mulder^{1,5} · Eric van Roon^{3,6} · Roberto Bakker^{7,8} · Henricus Ruhé^{2,9,10}

Published online: 17 August 2018
© Springer Nature Switzerland AG 2018

We thank Dr. Braillon for his comments on our article [1]. Dr. Braillon questions whether we should minimize the risk of proarrhythmia and sudden cardiac death in relation to antidepressants with recommendations for electrocardiogram monitoring or avoid the use of antidepressants all together and mainly treat patients with depression with psychotherapy [2]. We agree with Dr. Braillon that psychotherapy (cognitive behavioral therapy) is an alternative first-line treatment option for depression with at least better and prolonged effects regarding relapse prevention relative to antidepressants [3–5]. However, the aim of our article was to aid physicians and patients who have collaboratively decided to start antidepressant therapy to treat depression either as monotherapy or in combination with psychotherapy [1, 6]. We describe a set of recommendations for estimating and minimizing the risk of proarrhythmia and sudden cardiac death after the choice for pharmacological therapy above other treatment options has been made [1].

For decades, there has been a debate about the efficacy, effectiveness, and benefit-harm ratio of antidepressants. A recent systematic review and network analysis that was not yet available when Prescrire published its list of drugs to avoid in 2017 [7] represents the most comprehensive analysis of the evidence base for antidepressant efficacy and acceptability ever performed [8]. Based on 552 trials and over 116,000 participants, Cipriani et al. found that all 21 antidepressants included in the meta-analysis were more efficacious than placebo in adults with major depressive disorder, while few differences were found between the antidepressants and placebo when tolerability was concerned [8]. In fact, treatment with antidepressants can be lifesaving. Patients with major depressive disorder more often die from suicide than from proarrhythmia or sudden cardiac death. Although the risk of intentional overdosing as a consequence of psychiatric disease is always present, the literature currently available shows that adults aged over 25 years treated with any class of antidepressant have a lower risk of suicidality compared with placebo [9, 10]. We agree with Dr. Braillon that risks associated with any drug

This reply refers to the article available at <https://doi.org/10.1007/s40264-018-0714-7>.

✉ Henricus Ruhé
eric.ruhe@radboudumc.nl

¹ Department of Clinical Pharmacy, Wilhelmina Hospital Assen, Assen, The Netherlands

² Department of Psychiatry, Radboudumc, PO-Box 9101, 6500 HB Nijmegen, The Netherlands

³ Unit of Pharmacotherapy, Epidemiology and-Economics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands

⁴ Department of Research and Innovation, GGZ InGeest, Amsterdam, The Netherlands

⁵ Psychiatric Hospital GGZ Drenthe, Assen, The Netherlands

⁶ Department of Clinical Pharmacy and Clinical Pharmacology, Medical Centre Leeuwarden, Leeuwarden, The Netherlands

⁷ Psychiatric Centre GGZ Centraal, Amersfoort, The Netherlands

⁸ Department of Psychiatry and Psychology, South Limburg Mental Health and Teaching Network, Maastricht University Medical Centre, Maastricht, The Netherlands

⁹ Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK

¹⁰ Department of Psychiatry, Radboudumc, Nijmegen, The Netherlands

could be prevented by avoiding such agents and considering alternatives (e.g., psychotherapy) instead. Considering the data from the aforementioned meta-analyses, however, the suggested market withdrawal for antidepressants such as citalopram, escitalopram, and venlafaxine [7] is, in our opinion, too far reaching.

Once the choice for antidepressant therapy has been made, in our opinion, it is important to minimize the risk of proarrhythmia and sudden cardiac death. Currently, the only way to achieve risk minimization with respect to these adverse effects of antidepressants is to monitor the electrocardiogram based on risk factors such as older age, female sex, or aberrant potassium levels. We provide clear and readily applicable recommendations for performing electrocardiogram screening and monitoring in daily clinical practice, thereby meeting a need of clinicians that we identified.

We hope we were able to clarify the issues raised by Dr. Braillon and would like to thank him again for his reflections on our work.

Compliance with Ethical Standards

Funding No specific funding was received for this letter. The original project was funded by the Dutch Network for Quality Development in Mental Health Care (Grants P140019 and P140040 to Henricus Ruhé and Roberto Bakker). This organization had no influence on the content of the study, the original manuscript, or this letter.

Conflict of interest Henricus Ruhé obtained an Investigator-Initiated Trial grant and speaking fees from Lundbeck BV, which are not related to the current work. Mirjam Simoons, Adrie Seldenrijk, Hans Mulder, Eric van Roon, and Roberto Bakker have no conflicts of interest that are directly relevant to the contents of the study, the original manuscript, or this letter.

Ethics approval Ethics approval was not applicable for this letter.

Patient consent Patient consent was not applicable for this letter.

References

1. Simoons M, Seldenrijk A, Mulder H, Birkenhager T, Groothedde-Kuyvenhoven M, Kok R, et al. Limited evidence for risk factors for proarrhythmia and sudden cardiac death in patients using antidepressants: Dutch Consensus on ECG Monitoring. *Drug Saf.* 2018;41:655–64.
2. Braillon A. Comment on: “Limited evidence for risk factors for proarrhythmia and sudden cardiac death in patients using antidepressants: Dutch Consensus on ECG Monitoring”. *Drug Saf.* 2018. <https://doi.org/10.1007/s40264-018-0714-7>.
3. Spijker J, Bockting CLH, Meeuwissen JAC, Vliet van IM, Emmelkamp PMG, Hermens MLM, et al. Multidisciplinary guideline depression (third revision) [in Dutch]. 2013. <https://www.ggzrichtlijnen.nl/depressie>. Accessed 19 Jul 2018.
4. National Institute for Health and Care Excellence. Depression in adults: recognition and management (CG 90). 2009. <https://www.nice.org.uk/guidance/cg90>. Accessed 19 Jul 2018.
5. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 2010. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Accessed 19 Jul 2018.
6. Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF 3rd. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. *World Psychiatry.* 2014;13:56–67.
7. Prescrire. Towards better patient care: drugs to avoid in 2017. *Rev Prescrire.* 2017;37:137–48.
8. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet.* 2018;391:1357–66.
9. Gibbons RD, Brown CH, Hur K, Davis J, Mann JJ. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. *Arch Gen Psychiatry.* 2012;69:580–7.
10. Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes a, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. *BMJ.* 2009;339:b2880.